Literature DB >> 9778071

Differential effects of fosinopril and enalapril in patients with mild to moderate chronic heart failure. Fosinopril in Heart Failure Study Investigators.

F Zannad1, Z Chati, M Guest, F Plat.   

Abstract

OBJECTIVES: To investigate the efficacy and safety of fosinopril in the treatment of chronic heart failure (CHF), patients with mild to moderate CHF and left ventricular ejection fractions <40% were randomly assigned in a double-blind manner to receive fosinopril 5 to 20 mg every day (n = 122) or enalapril 5 to 20 mg every day (n = 132) for 1 year.
RESULTS: The event-free survival time was longer (1.6 vs 1.0 months, P= .032) and the total rate of hospitalizations plus deaths was smaller with fosinopril than with enalapril (19.7% vs 25.0%, P= .028). There was consistently better symptom improvement with fosinopril (P< .05). The incidence of orthostatic hypotension was lower in the fosinopril group (1.6% vs 7.6%, P< .05).
CONCLUSIONS: Fosinopril 5 to 20 mg every day was more effective in improving symptoms and delaying events related to worsening of CHF and produced less orthostatic hypotension than enalapril 5 to 20 mg every day.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9778071     DOI: 10.1016/s0002-8703(98)70015-8

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  2 in total

Review 1.  Renal artery stenosis as a cause of renal impairment: implications for treatment of hypertension and congestive heart failure.

Authors:  J E Scoble
Journal:  J R Soc Med       Date:  1999-10       Impact factor: 5.344

2.  Are patients in heart failure trials representative of primary care populations? A systematic review.

Authors:  Nicholas D Gollop; John Ford; Pieter Mackeith; Caroline Thurlow; Rachel Wakelin; Nicholas Steel; Robert Fleetcroft
Journal:  BJGP Open       Date:  2018-04-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.